Drugs & TargetsFree Keytruda receives positive EU CHMP opinion for expanded approval in some cases of relapsed or refractory classical hodgkin Lymphoma February 05, 2021Vol.47 No.05
Clinical RoundupFree More than half of cancer survivors have underlying medical conditions associated with severe COVID-19 February 05, 2021Vol.47 No.05
Clinical RoundupFree Gene mutations linked to worse outcomes from leukemia in Hispanic and Latino children February 05, 2021Vol.47 No.05
Clinical RoundupFree Queen’s leading new research aimed at improving outcomes for early-stage bowel cancer February 05, 2021Vol.47 No.05
Clinical RoundupFree Yale Cancer Center researchers discover mechanism to overcome drug-resistance in B-ALL February 05, 2021Vol.47 No.05
Clinical RoundupFree IU cancer center researchers discover how breast cancer cells hide from immune attack February 05, 2021Vol.47 No.05
Clinical RoundupFree Fecal microbiota transplants help patients with advanced melanoma respond to immunotherapy February 05, 2021Vol.47 No.05
Clinical RoundupFree Targeted RNA nanoparticle shows early promise as liver cancer treatment February 05, 2021Vol.47 No.05
Clinical RoundupFree KEYNOTE-598: Keytruda + Yervoy did not improve OS, PFS in Non-Small Cell Lung Cancer February 05, 2021Vol.47 No.05
FreeTrials & Tribulations The Delaware experience:Keeping in contact with those at risk is key to colorectal and breast cancer screening during COVID-19 February 05, 2021Vol.47 No.05By Nicholas J. Petrelli, Nora Katurakes, Rose Mili and Charlene Marinelli
